Neulastim

Neulastim® (pegfilgrastim, 6 mg in 0.6 mL PFS) is a Prescription Medicine used for reducing the duration and incidence of neutropenia (decrease in white blood cells) and infection, in patients treated with chemotherapy. Neulastim should not be used if you have had an allergic reaction to Neulastim, filgrastim (Neupogen®), E-coli-derived proteins or any of the ingredients listed on the medicine pack; if you are currently receiving chemotherapy or radiotherapy, or have received chemotherapy in the last 24 hours. Tell your doctor if you have other health problems, including myelodysplastic syndrome, leukaemia, spleen problems, sickle cell disease, you are receiving high dose chemotherapy, you are pregnant or plan to become pregnant or are breastfeeding. Possible unwanted effects: nausea, vomiting, headache, bone, joint or muscle pain; swelling, pain or itching at injection site; skin rash or red itchy spots, breathlessness, difficulty breathing, pain in the chest area. Ask your doctor if Neulastim is right for you. Use strictly as directed. If symptoms continue or you experience side effects or would like further information, please talk to your health professional or visit www.medsafe.govt.nz for Neulastim Consumer Medicines Information.

Neulastim is listed under Part II and Part IV of Section H of the Pharmaceutical Schedule. Funding is at the discretion of the DHB.

Neulastim® is sold under license from Amgen Inc. Neulastim® is a trademark of Amgen Inc. Consumer panel dated 5 December 2011, based on CMI dated 31 March 2011. Roche Products (New Zealand) Limited, Auckland; Phone 0800 656 464. www.roche.co.nz. All trademarks mentioned herein are protected by law.

For more information please view the Neulastim Consumer Medicine Information. Access to this site is subject to the terms in our Legal Statement; you accept these terms by continuing to access this site. ID1128/DA4011BR/2011DEC.